These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 1315294

  • 1. Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The "Petites Cellules" Group.
    Lebeau B, Chastang C, Allard P, Migueres J, Boita F, Fichet D.
    Eur Respir J; 1992 Mar; 5(3):286-90. PubMed ID: 1315294
    [Abstract] [Full Text] [Related]

  • 2. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R, Shin DM, Glisson BS, Fossella FV, Murphy WK, Garden AS, Oswald MJ, Hong WK, Roth JA, Peters LJ.
    Int J Radiat Oncol Biol Phys; 1995 Feb 15; 31(4):807-11. PubMed ID: 7860392
    [Abstract] [Full Text] [Related]

  • 3. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group.
    Urban T, Chastang C, Lebas FX, Duhamel JP, Adam G, Darse J, Bréchot JM, Lebeau B.
    Cancer; 1999 Dec 01; 86(11):2238-45. PubMed ID: 10590363
    [Abstract] [Full Text] [Related]

  • 4. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D, Graziano F, Mari D, Cetto G, Pasini F, Antonio S, Isidori P, Gasparini S.
    Anticancer Res; 1994 Dec 01; 14(5B):2221-7. PubMed ID: 7840527
    [Abstract] [Full Text] [Related]

  • 5. A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. "Petites Cellules" Group.
    Lebeau B, Urban T, Bréchot JM, Paillotin D, Vincent J, Leclerc P, Meekel P, L'Her P, Lebas FX, Chastang C.
    Cancer; 1999 Oct 15; 86(8):1480-7. PubMed ID: 10526276
    [Abstract] [Full Text] [Related]

  • 6. Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer.
    Lebeau B, Chouaïd C, Baud M, Masanès MJ, Febvre M.
    Lung Cancer; 2010 Feb 15; 67(2):188-93. PubMed ID: 19394109
    [Abstract] [Full Text] [Related]

  • 7. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May 15; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 8. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb 15; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 9. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC, McCrystal MR, Christmas TI.
    N Z Med J; 1998 Nov 27; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [Abstract] [Full Text] [Related]

  • 10. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer.
    Messeih AA, Schweitzer JM, Lipton A, Harvey HA, Simmonds MA, Stryker JA, Ricci JA, Hoffman SL, Gottleib RJ, Dixon RH.
    Cancer Treat Rep; 1987 Jan 27; 71(1):61-6. PubMed ID: 3024828
    [Abstract] [Full Text] [Related]

  • 11. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT, Bakker W, Koolen MG, Vendrik CP, Roozendaal KJ.
    J Clin Oncol; 1993 Jul 27; 11(7):1230-40. PubMed ID: 8391065
    [Abstract] [Full Text] [Related]

  • 12. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
    Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D, Murray PA, Ruiz de Elvira MC, O'Donnell KM, Gower NH, Harper PG, Hackshaw AK, London Lung Cancer Group.
    J Clin Oncol; 2006 Aug 20; 24(24):3823-30. PubMed ID: 16921033
    [Abstract] [Full Text] [Related]

  • 13. Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
    Aisner J, Whitacre M, Van Echo DA, Wiernik PH.
    Cancer Treat Rep; 1982 Feb 20; 66(2):221-30. PubMed ID: 6275987
    [Abstract] [Full Text] [Related]

  • 14. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
    Shepherd FA, Evans WK, MacCormick R, Feld R, Yau JC.
    Cancer Treat Rep; 1987 Oct 20; 71(10):941-4. PubMed ID: 2820571
    [Abstract] [Full Text] [Related]

  • 15. Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).
    Yuen AR, Fuks JZ, Ettinger DS, Chang AY, Ruckdeschel JC, Phan SC, Blum RH.
    Cancer J Sci Am; 2000 Oct 20; 6(1):34-9. PubMed ID: 10696737
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H, Kiura K, Tabata M, Kamei H, Gemba K, Sakae K, Hiraki Y, Hiraki S, Segawa Y, Harada M.
    Cancer; 1998 Jul 15; 83(2):283-90. PubMed ID: 9669811
    [Abstract] [Full Text] [Related]

  • 17. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR, Hatfield AK, Hillman S, Bauman MD, Mailliard JA, Kugler JW, Morton RF, Marks RS, Levitt R.
    Cancer; 2003 May 15; 97(10):2498-503. PubMed ID: 12733149
    [Abstract] [Full Text] [Related]

  • 18. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A, Fusco V, Pennucci C, Baldini E, Orsatti M, Vitale V, Bonavia M, Baracco F, Mereu C, Rosso R.
    Anticancer Res; 1991 May 15; 11(2):681-4. PubMed ID: 1648333
    [Abstract] [Full Text] [Related]

  • 19. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov 15; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 20. Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
    Osterlind K, Hansen M, Hirsch FR, Dombernowsky P, Sörenson S, Pedersen AG, Hansen HH.
    Ann Oncol; 1991 Jan 15; 2(1):41-6. PubMed ID: 1848996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.